DekaBank Deutsche Girozentrale Purchases Shares of 30,000 Travere Therapeutics, Inc. (NASDAQ:TVTX)

DekaBank Deutsche Girozentrale purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 30,000 shares of the company’s stock, valued at approximately $280,000.

Several other large investors also recently added to or reduced their stakes in TVTX. US Bancorp DE boosted its position in shares of Travere Therapeutics by 1,372.3% during the 1st quarter. US Bancorp DE now owns 1,487 shares of the company’s stock valued at $38,000 after acquiring an additional 1,386 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Travere Therapeutics by 31.0% in the third quarter. Tower Research Capital LLC TRC now owns 7,929 shares of the company’s stock valued at $71,000 after purchasing an additional 1,876 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Travere Therapeutics by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock valued at $78,000 after purchasing an additional 6,773 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Travere Therapeutics by 21.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,016 shares of the company’s stock worth $92,000 after acquiring an additional 1,074 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of Travere Therapeutics by 29.2% in the 2nd quarter. Royal Bank of Canada now owns 7,655 shares of the company’s stock worth $117,000 after purchasing an additional 1,732 shares in the last quarter.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CEO Eric M. Dube sold 7,873 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $8.96, for a total transaction of $70,542.08. Following the completion of the sale, the chief executive officer now directly owns 234,722 shares in the company, valued at approximately $2,103,109.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Travere Therapeutics news, CEO Eric M. Dube sold 7,873 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $8.96, for a total value of $70,542.08. Following the transaction, the chief executive officer now directly owns 234,722 shares in the company, valued at $2,103,109.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP William E. Rote sold 4,764 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total transaction of $41,494.44. Following the sale, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,030 shares of company stock valued at $419,773. 4.06% of the stock is owned by company insiders.

Travere Therapeutics Stock Down 2.7 %

TVTX stock opened at $6.15 on Wednesday. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. Travere Therapeutics, Inc. has a 1-year low of $5.25 and a 1-year high of $22.75. The stock has a market capitalization of $468.08 million, a P/E ratio of -3.82 and a beta of 0.58. The business has a fifty day moving average price of $7.72 and a 200-day moving average price of $7.77.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.11. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The business had revenue of $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Equities analysts forecast that Travere Therapeutics, Inc. will post -3.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TVTX. Guggenheim reiterated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Wedbush reissued an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a research note on Friday, February 16th. Wells Fargo & Company raised their price target on Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Friday, February 16th. Piper Sandler lifted their price target on Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Thursday, January 18th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Travere Therapeutics in a research note on Wednesday, March 13th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.85.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.